Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.
Xu-Monette, et al.
Blood Adv. 2026.
Hi-C FFPE Sequencing for Detection of Fusions andRearrangements that are Diagnostic, Prognostic, andTherapeutic Biomarkers in Lymphoma
Xu-Monette, et al.
AMP Europe 2026 - Tallinn, Estonia
Hi-C Sequencing Outperforms High-Coverage WGSfor Detection of Diagnostic Fusions and Rearrangementsin FFPE Lymphoma Specimens
Sikkink, et al.
AMP Europe 2026 - Tallinn, Estonia
Hi-C sequencing to identify clinically actionable fusions in non–small cell lung cancer missed by other sequencing technologies
Levine, et al.
ASCO 2026 - Chicago, IL
Discovery and functional characterization of enhancer hijacking oncogene rearrangements in NSCLC using Hi-C sequencing of FFPE tumors
Sikkink, et al.
AACR 2026 - San Diego, CA
Detection and functional assessment of extrachromosomal DNA amplifications in FFPE lung tumor specimens using Hi-C sequencing
Sikkink, et al.
AACR 2026 - San Diego, CA
Genome wide testing of archived ovarian and uterine carcinosarcoma FFPE tissue using FusionPlus Hi-C to determine HRD status
Bradshaw, et al.
AACR 2026 - San Diego, CA
Targetable fusions and rearrangement detection in gastrointestinal and lungtumors leveraging low-pass whole-genome sequencing based Hi-C chemistry
Sigal, et al.
AACR 2026 - San Diego, CA
Actionable fusions and rearrangements can be efficiently identified by Hi-C whole genome sequencing in lung tumors
Hastie, et al.
AACR 2026 - San Diego, CA
Hi-C for genome-wide detection of enhancer-hijacking rearrangements in routine lymphoid cancer biopsies
Wu, et al.
Cell Genomics. 6(5):101166.
